Reuters logo
BRIEF-Ohr pharmaceutical reports Q1 loss per share $0.21
February 14, 2017 / 12:23 PM / 10 months ago

BRIEF-Ohr pharmaceutical reports Q1 loss per share $0.21

Feb 14 (Reuters) - Ohr Pharmaceutical Inc

* Ohr Pharmaceutical announces strategic update and fiscal first quarter 2017 earnings

* Q1 loss per share $0.21

* For quarter ended december 31, 2016, total operating expenses were approximately $7.0 million

* Plan to continue study for currently enrolled patients to evaluate efficacy of squalamine combination therapy

* Ohr Pharmaceutical - has paused enrollment in first phase 3 clinical trial of its lead drug candidate squalamine lactate ophthalmic solution, 0.2%

* “enrollment pause is not related to any safety issue” Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below